KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Average (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Equity Average for 12 consecutive years, with $570.6 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 26.5% to $570.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $570.6 million through Dec 2025, down 26.5% year-over-year, with the annual reading at $668.3 million for FY2025, 20.57% down from the prior year.
  • Equity Average for Q4 2025 was $570.6 million at Xenon Pharmaceuticals, down from $596.7 million in the prior quarter.
  • The five-year high for Equity Average was $907.8 million in Q1 2024, with the low at $223.8 million in Q1 2021.
  • Average Equity Average over 5 years is $629.5 million, with a median of $667.8 million recorded in 2023.
  • The sharpest move saw Equity Average surged 204.18% in 2022, then fell 27.31% in 2025.
  • Over 5 years, Equity Average stood at $399.5 million in 2021, then skyrocketed by 84.56% to $737.3 million in 2022, then rose by 6.1% to $782.3 million in 2023, then decreased by 0.75% to $776.4 million in 2024, then decreased by 26.5% to $570.6 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $570.6 million, $596.7 million, and $669.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.